glp-1 and graves disease Genetics: How Genes Affect Appetite, Semaglutide, Tirzepatide Response GLP-1 and Gut Health: Addressing

HbA1c should be reviewed every 36 months initially, with ongoing monitoring of renal function at least annually or more frequently in patients with existing kidney impairment

The dosing schedule begins with a small introductory dosage of 0.25 mg and is increased slowly until a therapeutic dosage (a dose which provides good hunger suppression, minimal side effects, and consistent weight loss) is reached or the highest FDA-approved dose, 2.4 mg, is reached

This is accomplished by a series of equilibrium reactions in which 3 moles of ribulose-5-phosphate are converted into 2 moles of Fru-6-P and 1 mole of glyceraldehyde-3-phosphate

Yau M, Sperling M